icon-    folder.gif   Conference Reports for NATAP  
  17th CROI
Conference on Retroviruses
and Opportunistic Infections
San Francisco CA
February 16-19, 2010
Back grey_arrow_rt.gif
Mechanisms of Virologic Failure With Maraviroc in Treatment-Naïve HIV-1-Infected Patients Through 96 Weeks
  Reported by Jules Levin
17th CROI Feb 16-19 201 SF
Craig C1, Heera J2, Lewis M1, Simpson P1, Weatherley B1, van der Ryst E1, Goodrich J2, McFadyen L1, Perros M1, Westby M1 1Pfizer Global Research and Development, Sandwich, UK, 2Pfizer Global Research and Development, New London, CT, USA


a Three subjects who had never suppressed plasma HIV-1 RNA by Week 48 later responded to therapy.
b Includes 2 deaths.
c Discontinuation due to non-virologic failure at ≤ 42 days included 12 MVC-treated patients and 31 EFV-treated patients who remained viremic (plasma HIV-1 RNA > 50 c/mL) and therefore still at heightened risk of developing resistance.
d Plasma HIV-1 RNA.

a This is a sensitivity analysis and included all data from patients through Week 96, including those who remained on-therapy post-virologic failure (eg, in the MVC arm, 13 instances of M184V were observed a median of 84 days after virologic failure) and those who had stopped study therapy (eg, in the EFV arm, NNRTI resistance was observed in 4 patients after stopping EFV therapy).
b EFV, 3TC, and ZDV resistance were assessed using the 'net' PSGT call here, but used genotype in the analysis at the time of virologic failure.
c This analysis takes into account all observations; thus not all patients had full data sets.